Axim Biotechnologies, Inc. Just Filed Its Quarterly Report: Net Loss per Common ...

Net Loss per Common Share

 

Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common s tock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be anti-dilutive.

 

There were 16,047,678 common share equivalents at June 30, 2019 and 15,843,037 common shares at December 31, 2018. For the six months ended June 30, 2019 and 2018 these potential shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Axim Biotechnologies, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

AXIM® Biotechnologies Issues Update Letter to Shareholders - Oct. 28, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19) - Oct. 6, 2020
AXIM® Biotechnologies Files Patent for Virus Binding Recombinant Protein for SARS-CoV-2 (COVID-19) and Begins Manufacturing - Sept. 30, 2020

Auto Refresh

Feedback